A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.

Mucus stasis in chronic obstructive pulmonary disease (COPD) is a significant contributor to morbidity and mortality. Potentiators of cystic fibrosis transmembrane conductance regulator (CFTR) activity pharmacologically enhance CFTR function; ivacaftor is one such agent approved to treat CF patients...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Peter A Sloane, Suresh Shastry, Andrew Wilhelm, Clifford Courville, Li Ping Tang, Kyle Backer, Elina Levin, S Vamsee Raju, Yao Li, Marina Mazur, Suzanne Byan-Parker, William Grizzle, Eric J Sorscher, Mark T Dransfield, Steven M Rowe
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Public Library of Science (PLoS) 2012-01-01
Seri Bilgileri:	PLoS ONE
Online Erişim:	http://europepmc.org/articles/PMC3387224?pdf=render
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease.

Benzer Materyaller